# ë°°ê²½ ìë£Œ: S7 ë°”ì´ëŸ¬ìŠ¤ ì—°êµ¬ & íŒ¬ë°ë¯¹ ëŒ€ì‘

**ì„¸ì…˜**: S7 - Frontiers in Viral Research and Pandemic Response
**ì¼ì‹œ**: 2025ë…„ 10ì›” 27ì¼ (ì›”) 13:50-15:50
**ì¥ì†Œ**: Convention Hall 1
**Sponsored by**: International Vaccine Institute (IVI)
**Chair**: Jae-Ouk Kim (IVI) & Manki Song (IVI)
**ì¤‘ìš”ë„**: â­â­â­â­ (80/100ì ) - **ë°”ì´ëŸ¬ìŠ¤/ë°±ì‹  ì—°êµ¬ì í•„ìˆ˜!**

---

## ğŸ¯ ì„¸ì…˜ ê°œìš”

ì´ ì„¸ì…˜ì€ **ë°”ì´ëŸ¬ìŠ¤ ì—°êµ¬ì˜ ìµœì‹  ë™í–¥ê³¼ íŒ¬ë°ë¯¹ ëŒ€ì‘ ì „ëµ**ì„ ë‹¤ë£¹ë‹ˆë‹¤. IVI (êµ­ì œë°±ì‹ ì—°êµ¬ì†Œ)ê°€ í›„ì›í•˜ëŠ” ë§Œí¼ **ë°±ì‹  ê°œë°œ**ì— ì´ˆì ì´ ë§ì¶°ì ¸ ìˆìŠµë‹ˆë‹¤.

### ì™œ ì´ ì„¸ì…˜ì´ ì¤‘ìš”í•œê°€?

- ğŸ§¬ **AI ë°±ì‹  ê°œë°œ**: AlphaFold ì´í›„ ì‹œëŒ€ì˜ structure-based vaccine design
- ğŸ¦  **Host-directed therapy**: ë°”ì´ëŸ¬ìŠ¤ê°€ ì•„ë‹Œ ìˆ™ì£¼ë¥¼ íƒ€ê²Ÿ
- ğŸ’‰ **ì°¨ì„¸ëŒ€ í”Œë«í¼**: mRNA, nanoparticle, structure-based design
- ğŸŒ **íŒ¬ë°ë¯¹ ëŒ€ë¹„**: í•œêµ­ì˜ ë°±ì‹  R&D ì „ëµ

### ì´ ì„¸ì…˜ì˜ ê³µí†µ í…Œë§ˆ

```
íŒ¬ë°ë¯¹ ëŒ€ì‘ ì „ëµ
â”œâ”€ ìˆ™ì£¼ íƒ€ê²Ÿ ì¹˜ë£Œ (Host-directed therapy)
â”œâ”€ êµ¬ì¡° ê¸°ë°˜ ë°±ì‹  (Structure-based design)
â”œâ”€ AI í™œìš© (AlphaFold, RoseTTAFold)
â””â”€ ì‹ ì† ê°œë°œ í”Œë«í¼ (Rapid response platforms)
```

---

## ğŸ“‹ ë°œí‘œë³„ ìƒì„¸ ë¶„ì„

### ğŸ”¹ ë°œí‘œ 1 (13:50-14:20)

**ì—°ì‚¬**: Seungmin Hwang (í™©ìŠ¹ë¯¼)
**ì†Œì†**: Broad Institute of MIT and Harvard, USA
**ì œëª©**: Host-directed therapy for respiratory viral infection

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½ (2024-2025)

Hwang ë°•ì‚¬ëŠ” **2023ë…„ 9ì›” Broad Instituteì— í•©ë¥˜**í–ˆìœ¼ë©°, **host-directed therapy (HDT)** ì „ë¬¸ê°€ì…ë‹ˆë‹¤.

**ìµœì‹  ì—°êµ¬ (2025)**:

**PNAS (2025ë…„ 3ì›” accepted)**:
"Shared host genetic landscape of respiratory viral infection"

**í•µì‹¬ ë°œê²¬**:
- ë‹¤ì–‘í•œ **í˜¸í¡ê¸° ë°”ì´ëŸ¬ìŠ¤**ê°€ **ê³µí†µ ìˆ™ì£¼ ìœ ì „ì**ì— ì˜ì¡´
- **Broad-spectrum HDT** ê°€ëŠ¥ì„±
- **STT3A/B** (oligosaccharyltransferase) = ìœ ë§í•œ íƒ€ê²Ÿ
  - N-linked glycosylation ë‹´ë‹¹
  - ë°”ì´ëŸ¬ìŠ¤ê°€ ê°ì—¼ì— hijack

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. Host-Directed Therapy (HDT) ê°œë…**

**ì „í†µì  í•­ë°”ì´ëŸ¬ìŠ¤ì œ**:
```yaml
Target: ë°”ì´ëŸ¬ìŠ¤ ë‹¨ë°±ì§ˆ
  - Polymerase inhibitors (Remdesivir)
  - Protease inhibitors (Paxlovid)
  - Neuraminidase inhibitors (Tamiflu)

ë¬¸ì œì :
  - ë°”ì´ëŸ¬ìŠ¤ ë³€ì´ â†’ ë‚´ì„±
  - Virus-specific (narrow spectrum)
  - ê°œë°œ ì‹œê°„ ì˜¤ë˜ ê±¸ë¦¼
```

**Host-Directed Therapy**:
```yaml
Target: ìˆ™ì£¼ ì„¸í¬ ë‹¨ë°±ì§ˆ (ë°”ì´ëŸ¬ìŠ¤ê°€ ì˜ì¡´)
  - Endocytosis ì–µì œ
  - Glycosylation ì°¨ë‹¨
  - Immune modulation

ì¥ì :
  - ë‚´ì„± ë°œìƒ ì–´ë ¤ì›€ (ìˆ™ì£¼ ìœ ì „ì ë³€ì´ ëŠë¦¼)
  - Broad-spectrum (ì—¬ëŸ¬ ë°”ì´ëŸ¬ìŠ¤ì— íš¨ê³¼)
  - ì¬ì‚¬ìš© ê°€ëŠ¥ (drug repurposing)

ë‹¨ì :
  - Host toxicity ìš°ë ¤
  - Therapeutic window ì¢ì„ ìˆ˜ ìˆìŒ
```

**2. í˜¸í¡ê¸° ë°”ì´ëŸ¬ìŠ¤ì˜ ê³µí†µ ìˆ™ì£¼ ì˜ì¡´ì„±**

**ì£¼ìš” í˜¸í¡ê¸° ë°”ì´ëŸ¬ìŠ¤**:
- **Influenza A/B**: ê³„ì ˆì„± ë…ê°, íŒ¬ë°ë¯¹
- **SARS-CoV-2**: COVID-19
- **RSV**: ì˜ìœ ì•„ íë ´
- **HPIV** (Human parainfluenza): ì†Œì•„ í¬ë£¹
- **hMPV** (Human metapneumovirus)

**ê³µí†µ ìˆ™ì£¼ ê²½ë¡œ**:

**A. Entry (ì„¸í¬ ì¹¨íˆ¬)**:
```
Receptor binding
  â†“
Endocytosis (Clathrin/Caveolin-mediated)
  â†“
Endosome acidification
  â†“
Membrane fusion
  â†“
Viral genome release
```

**ê³µí†µ íƒ€ê²Ÿ**:
- **ACE2, TMPRSS2** (SARS-CoV-2)
- **Sialic acid** (Influenza, others)
- **Endosomal acidification** (V-ATPase)

**B. Replication**:
```
Host ribosomes, tRNA
  â†“
ER/Golgi (protein processing)
  â†“
Lipid synthesis
```

**C. Egress (ë°©ì¶œ)**:
```
Viral assembly
  â†“
Budding (ESCRT pathway)
  â†“
Release
```

**3. STT3A/B: ìœ ë§í•œ Broad-Spectrum Target**

**STT3A/B**:
- **Oligosaccharyltransferase (OST) complex** catalytic subunits
- **N-linked glycosylation** ë‹´ë‹¹
  - Asn-X-Ser/Thr motifì— glycan ë¶€ì°©
  - ER lumenì—ì„œ ë°œìƒ

**ë°”ì´ëŸ¬ìŠ¤ê°€ N-glycosylationì„ hijackí•˜ëŠ” ì´ìœ **:
```yaml
Viral envelope proteins (spike, HA, etc.):
  - N-glycans ë§ìŒ (glycan shield)
  - ë©´ì—­ íšŒí”¼ (antibody epitope ì°¨í)
  - Protein folding ë„ì›€
  - Receptor binding ì¡°ì ˆ

ì˜ˆì‹œ:
  - SARS-CoV-2 Spike: ~22 N-glycans
  - Influenza HA: ~5-11 N-glycans
  - HIV Env: ~30 N-glycans (ê·¹ë‹¨ì )
```

**STT3A/B ì–µì œì˜ íš¨ê³¼**:
```
N-glycosylation â†“
  â†“
Viral protein misfolding
  â†“
ER retention, degradation
  â†“
ê°ì—¼ì„± virion ìƒì‚° â†“
```

**ì¥ì **:
- **Broad-spectrum**: ê±°ì˜ ëª¨ë“  enveloped virus íƒ€ê²Ÿ
- **í•„ìˆ˜ ê²½ë¡œ**: ë°”ì´ëŸ¬ìŠ¤ê°€ ìš°íšŒí•˜ê¸° ì–´ë ¤ì›€

**ë‹¨ì **:
- **Host toxicity**: ì¸ê°„ glycoproteinë„ ì˜í–¥
- **Therapeutic window**: ì¼ì‹œì  ì–µì œ í•„ìš”

**4. Genetic Evidence (PNAS 2025)**

**Approach**:
```python
# Genome-wide CRISPR screen
1. Human cell library (ê° ìœ ì „ì knockout)
2. Virus infection (Influenza, SARS-CoV-2, etc.)
3. Survival selection
4. Sequencing (ì–´ë–¤ knockoutì´ ìƒì¡´?)
5. Common host factors ë™ì •

Result:
  - ìˆ˜ë°± ê°œ host genes identified
  - Pathway analysis:
    - Glycosylation (STT3A/B, DDOST, etc.)
    - Endocytosis (AP2, Dynamin)
    - Membrane trafficking (SNAREs)
```

**Shared genes across viruses**:
- **STT3A/B**: Influenza, SARS-CoV-2, RSV ëª¨ë‘ ì˜ì¡´
- **TMEM41B**: Flaviviruses, Coronaviruses
- **ATP6V0**: Endosomal acidification

**5. Clinical Perspective**

**ê¸°ì¡´ HDT ì˜ˆì‹œ**:
- **Chloroquine**: Endosomal pH â†‘ (ë§ë¼ë¦¬ì•„ ì•½, ì¬ì‚¬ìš©)
- **IFN-Î±/Î²**: Immune stimulation (HCV ì¹˜ë£Œ)
- **JAK inhibitors**: Cytokine storm ì–µì œ (COVID-19)

**STT3A/B inhibitors ê°œë°œ**:
- **NGI-1**: STT3 ì–µì œì œ (ì—°êµ¬ìš©)
- **In vivo efficacy**: ë™ë¬¼ ëª¨ë¸ í…ŒìŠ¤íŠ¸ í•„ìš”
- **Toxicity profiling**: í•„ìˆ˜

**Combination therapy**:
```
HDT (STT3i) + Antiviral (Remdesivir)
  â†“
Synergy:
  - ë°”ì´ëŸ¬ìŠ¤ ë³µì œ â†“â†“
  - ë‚´ì„± ë°œìƒ â†“
  - ì¹˜ë£Œ íš¨ê³¼ â†‘
```

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ë°”ì´ëŸ¬ìŠ¤í•™ ì‹¤í—˜ì‹¤ ê´€ì **:

**1. CRISPR Screen**:
```python
# Genome-wide host factor screen
1. Library: Brunello, GeCKO (human genome-wide)
2. Transduction: Lentiviral sgRNA library
3. Selection: Puromycin
4. Infection: MOI 0.1-1
5. Timepoint: 3-7 days post-infection
6. Sequencing: NGS (sgRNA abundance)
7. Analysis: MAGeCK, BAGEL
```

**2. HDT Validation**:
```yaml
In vitro:
  - Dose-response (IC50)
  - Cytotoxicity (CC50)
  - Selectivity index (SI = CC50/IC50)
  - Viral titer reduction (plaque assay, qPCR)

In vivo:
  - Mouse models (K18-hACE2, BALB/c)
  - Viral load (lung, blood)
  - Pathology (H&E staining)
  - Survival
```

**3. Drug Repurposing**:
- FDA-approved drugs screen
- Off-target effects
- Clinical trials ë¹ ë¦„

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. N-Linked Glycosylation**
```
Asn-X-Ser/Thr motif (X â‰  Pro)
  â†“
Dolichol-PP-GlcNAc2Man9Glc3 (precursor)
  â†“
OST (STT3A/B) transfer
  â†“
Glycan attached to Asn
  â†“
Glucosidase trimming
  â†“
Calnexin/Calreticulin (folding)
```

**2. Viral Glycan Shield**
- **High-density glycans**: Antibody ì ‘ê·¼ ì°¨ë‹¨
- **Evolution**: Glycan site ì¦ê°€ (immune escape)
- **Vaccine design**: Glycan ê³ ë ¤ í•„ìˆ˜

**3. Therapeutic Window**
- **Narrow window**: Host í•„ìˆ˜ vs. ë°”ì´ëŸ¬ìŠ¤ ì˜ì¡´
- **Transient inhibition**: ê¸‰ì„± ê°ì—¼ ì‹œ ë‹¨ê¸° ì‚¬ìš©

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ì§ˆë¬¸**:
1. "**STT3A vs. STT3B** ì¤‘ ì–´ëŠ ê²ƒì´ ë” ì¤‘ìš”í•œ íƒ€ê²Ÿ? Redundancy?"
2. "**ì¥ê¸° íˆ¬ì—¬ ì‹œ host toxicity**ëŠ”? ë§Œì„± ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼ì— ì‚¬ìš© ê°€ëŠ¥?"
3. "**ë°”ì´ëŸ¬ìŠ¤ ë³€ì´**ë¡œ N-glycosylation íšŒí”¼ ê°€ëŠ¥? ë‚´ì„± ë©”ì»¤ë‹ˆì¦˜?"
4. "**ë‹¤ë¥¸ HDT targets** (TMEM41B ë“±)ì™€ combination?"
5. "**ì„ìƒ ì‹œí—˜** ê³„íš? Phase I ì‹œì‘?"

---

### ğŸ”¹ ë°œí‘œ 2 (14:20-14:50)

**ì—°ì‚¬**: Jae-Hyun Park (ë°•ì¬í˜„)
**ì†Œì†**: Sungkyunkwan University School of Medicine
**ì œëª©**: Structural insight into HBV receptor NTCP and virus binding

#### ì—°êµ¬ ë°°ê²½

**HBV (Hepatitis B Virus)**:
- ë§Œì„± ê°„ì—¼, ê°„ê²½í™”, ê°„ì•” ì›ì¸
- ì „ ì„¸ê³„ 2ì–µ 9ì²œë§Œ ëª… ê°ì—¼
- **NTCP** (Naâº-taurocholate co-transporting polypeptide) = ìˆ˜ìš©ì²´

**NTCP**:
- **ë‹´ì¦™ì‚° ìˆ˜ì†¡ì²´**: ê°„ì„¸í¬ í‘œë©´
- **HBV entry**: Pre-S1 domain ê²°í•©

#### ì˜ˆìƒ ë‚´ìš©

**1. NTCP êµ¬ì¡° (Cryo-EM)**
- **10 transmembrane domains**
- **Naâº binding site**
- **Bile acid binding pocket**

**2. HBV-NTCP ìƒí˜¸ì‘ìš©**
- **Pre-S1 (2-48 aa)**: Viral attachment site
- **Myristoylation**: N-terminal lipid modification (í•„ìˆ˜)
- **Binding interface**: NTCP extracellular loops

**3. Entry Inhibitors**
- **Myrcludex B**: NTCP-HBV ê²°í•© ì°¨ë‹¨
  - HDV (Hepatitis D) ìŠ¹ì¸
  - HBV Phase III

**4. êµ¬ì¡° ê¸°ë°˜ ì•½ë¬¼ ì„¤ê³„**
- **Small molecules**: NTCP binding pocket
- **Peptide inhibitors**: Pre-S1 mimics

---

### ğŸ”¹ ë°œí‘œ 3 (14:50-15:20) â­ **í•µì‹¬!**

**ì—°ì‚¬**: Minkyung Baek (ë°±ë¯¼ê²½)
**ì†Œì†**: Seoul National University (ì„œìš¸ëŒ€í•™êµ), Department of Biological Sciences
**ì œëª©**: Transforming vaccine development with AI: Recent trends and structure-based strategies

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½ (2024-2025)

Baek êµìˆ˜ëŠ” **2025ë…„ APEC ASPIRE Prize ìˆ˜ìƒì** (í•œêµ­ì¸ ìµœì´ˆ!)ì´ë©°, **AI ë‹¨ë°±ì§ˆ êµ¬ì¡° ì˜ˆì¸¡** ì „ë¬¸ê°€ì…ë‹ˆë‹¤.

**í•µì‹¬ ì—…ì **:
- **RoseTTAFold** co-developer (David Baker lab)
  - AlphaFold competitor
  - 2021ë…„ Science ë°œí‘œ
- **2025ë…„ LG AI Research í˜‘ë ¥**: ì°¨ì„¸ëŒ€ ë‹¨ë°±ì§ˆ êµ¬ì¡° ì˜ˆì¸¡ AI ê°œë°œ

**ë°±ì‹  ê°œë°œ ê´€ë ¨**:
- **Structure-based vaccine design**
- **Epitope prediction**
- **Protein stability optimization**

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. AI Protein Structure Prediction í˜ëª…**

**AlphaFold2 (2020)**:
```yaml
Impact:
  - ë‹¨ë°±ì§ˆ êµ¬ì¡° ì˜ˆì¸¡ ì •í™•ë„ 90%+
  - ì›ì ìˆ˜ì¤€ resolution
  - 200 million+ structures (AlphaFold DB)

Limitations:
  - Single chain ìœ„ì£¼
  - ë™ì  êµ¬ì¡° (conformational changes) ì•½í•¨
  - Membrane proteins ì–´ë ¤ì›€
```

**RoseTTAFold (Baek et al. 2021)**:
```yaml
Features:
  - 3-track architecture (1D, 2D, 3D)
  - Protein-protein complexes ê°€ëŠ¥
  - Speed: AlphaFoldë³´ë‹¤ ë¹ ë¦„

Applications:
  - Antibody-antigen docking
  - Multi-subunit complexes
  - Protein design (ì—­ë°©í–¥)
```

**ì°¨ì„¸ëŒ€ ëª¨ë¸ (2024-2025)**:
- **AlphaFold3**: Multi-chain, ligands, DNA/RNA
- **RoseTTAFold All-Atom**: Small molecules, ions
- **ESMFold**: Language model-based (Meta)

**2. Structure-Based Vaccine Design**

**ì „í†µì  ë°©ë²•**:
```
Pathogen isolation
  â†“
Whole organism (killed/attenuated)
  or Subunit (purified protein)
  â†“
Trial & error
  â†“
10-15ë…„ ê°œë°œ ê¸°ê°„
```

**AI-driven approach**:
```
Pathogen genome
  â†“
AI structure prediction (AlphaFold)
  â†“
Epitope identification (B/T cell epitopes)
  â†“
Antigen design (stabilized, optimized)
  â†“
In silico validation
  â†“
Rapid prototyping (mRNA, nanoparticle)
  â†“
2-3ë…„
```

**3. Epitope Prediction with AI**

**B-cell epitopes**:
- **Surface accessibility**: Exposed loops, termini
- **Antigenicity**: Antibody binding propensity
- **Conservation**: Sequence variability ë‚®ìŒ

**AI tools**:
```python
# B-cell epitope prediction
1. Structure prediction (AlphaFold)
2. Surface area calculation (SASA)
3. Antigenicity scoring (ML models)
4. Conservation analysis (MSA)
5. Ranking top epitopes
```

**T-cell epitopes**:
- **MHC binding**: HLA-A, HLA-B, HLA-DR
- **Peptide presentation**: 8-11mer (Class I), 13-25mer (Class II)

**AI tools**:
- **NetMHCpan**: Deep learning MHC binding
- **AlphaFold-Multimer**: Peptide-MHC complex

**4. Antigen Stabilization (êµ¬ì¡° ê¸°ë°˜)**

**ë¬¸ì œ**: Viral surface proteins ë¶ˆì•ˆì •
- **Pre-fusion** (ê°ì—¼ ì „) â†” **Post-fusion** (ê°ì—¼ í›„)
- ë°±ì‹ ì€ pre-fusion conformation í•„ìš” (ì¤‘í™” í•­ì²´ íƒ€ê²Ÿ)

**ì˜ˆì‹œ: RSV F protein**:
```
Native F protein:
  - Metastable (pre-fusion)
  - Fusion í›„ post-fusion (ì•ˆì •)
  - ë°±ì‹  í•­ì›ìœ¼ë¡œ ë¶€ì í•©

Stabilized F protein (DS-Cav1):
  - Structure-based design (Jason McLellan)
  - Disulfide bond, proline substitutions
  - Pre-fusion locked
  - â†’ mRNA vaccine (Moderna, Pfizer)
```

**AI í™œìš©**:
```
AlphaFold prediction
  â†“
Conformational analysis (MD simulations)
  â†“
Mutation design (stability â†‘)
  â†“
In silico screening
  â†“
Experimental validation
```

**5. Nanoparticle Vaccine Platforms**

**Ferritin, I53-50 ë“±**:
- **Self-assembling**: 24-60 subunits
- **Antigen display**: Surfaceì— epitopes ì œì‹œ
- **Multivalent**: B-cell activation â†‘

**AI design**:
```yaml
Process:
  1. Antigen selection (epitope)
  2. Scaffold design (nanoparticle core)
  3. Linker optimization (flexibility)
  4. AlphaFold validation
  5. Cryo-EM structure determination

Example:
  - Mosaic nanoparticle (multiple virus strains)
  - Pan-coronavirus vaccine
```

**6. COVID-19 ë°±ì‹  ê°œë°œ ì‚¬ë¡€**

**Spike protein structure** (Cryo-EM, 2020):
- **Pre-fusion stabilization**: 2P mutations (K986P, V987P)
  - Moderna, Pfizer/BioNTech mRNA vaccines
  - Structure-based design ì„±ê³µ!

**Omicron variant** (2021):
- **AlphaFold2 prediction**: Spike mutations
- **Epitope mapping**: Antibody escape
- **Booster design**: ì‹ ì†í•œ ë³€ì´ ëŒ€ì‘

**7. Universal Vaccine Strategies**

**ëª©í‘œ**: ëª¨ë“  ë³€ì´/ê³„ì ˆí˜•ì— íš¨ê³¼

**Approaches**:
- **Conserved epitopes**: Stem region (Influenza HA)
- **Mosaic antigens**: ì—¬ëŸ¬ strain í˜¼í•©
- **Computationally optimized breadth (COB)**: AIë¡œ ìµœì  ì¡°í•©

**AI ì—­í• **:
```python
# Universal epitope discovery
1. ìˆ˜ì²œ ê°œ viral sequences alignment
2. Conservation analysis
3. AlphaFold structure prediction (all variants)
4. Epitope accessibility check
5. Immunogenicity scoring
6. Top candidates selection
```

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ë°±ì‹ í•™ ì‹¤í—˜ì‹¤ ê´€ì **:

**1. AlphaFold/RoseTTAFold í™œìš©**:
```python
# Practical workflow
1. Target protein sequence (FASTA)
2. AlphaFold/RoseTTAFold prediction
3. pLDDT (confidence) í™•ì¸
4. PyMOL visualization
5. Epitope mapping (manual or tools)
6. Mutation design (stabilization, affinity â†‘)
7. Experimental validation (binding assays)
```

**2. Epitope Mapping Tools**:
| Tool | Function | Input |
|------|----------|-------|
| **BepiPred3.0** | B-cell epitope | Sequence + Structure |
| **NetMHCpan** | MHC-I/II binding | Peptide sequence |
| **IEDB** | Epitope database | Pathogen name |
| **DiscoTope** | Discontinuous epitopes | Structure (PDB) |

**3. êµ¬ì¡° ê²€ì¦**:
- **Cryo-EM**: ê³ í•´ìƒë„ (~3 Ã…)
- **X-ray crystallography**: ì›ì ìˆ˜ì¤€
- **SAXS**: Solution structure
- **HDX-MS**: Conformational dynamics

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. AlphaFold Architecture**
```
Input: Multiple Sequence Alignment (MSA)
  â†“
Evoformer blocks (attention mechanisms)
  â†“
Structure module
  â†“
Output: 3D coordinates + pLDDT (confidence)
```

**2. Protein Stability**
- **Thermostability**: Tm (melting temperature)
- **Mutations**: Disulfide bonds, Pro substitutions
- **Folding energy**: Î”G (Rosetta, FoldX)

**3. Immunogen vs. Antigen**
- **Antigen**: í•­ì²´ê°€ ì¸ì‹í•˜ëŠ” molecule
- **Immunogen**: ë©´ì—­ ë°˜ì‘ ìœ ë°œí•˜ëŠ” antigen
- â†’ **Adjuvants** í•„ìš” (ë©´ì—­ ì¦ê°•)

**4. mRNA Vaccine**
- **Mechanism**: mRNA â†’ ì„¸í¬ ë‚´ ë²ˆì—­ â†’ í•­ì› ìƒì‚° â†’ ë©´ì—­ ë°˜ì‘
- **Advantages**: ë¹ ë¥¸ ê°œë°œ, ë³€ì´ ëŒ€ì‘
- **Challenges**: Stability (LNP), ë¶€ì‘ìš©

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ì§ˆë¬¸**:
1. "**AlphaFold3 vs. RoseTTAFold All-Atom** ë¹„êµ? ë°±ì‹  ì„¤ê³„ì— ì–´ëŠ ê²ƒì´ ë” ìœ ìš©?"
2. "**í•œêµ­í˜• ì°¨ì„¸ëŒ€ ë‹¨ë°±ì§ˆ AI** (LG í˜‘ë ¥)ì˜ íŠ¹ì§•? ë°±ì‹  ê°œë°œ íŠ¹í™”?"
3. "**Epitope drift** (ë³€ì´ë¡œ epitope ë³€í™”)ë¥¼ AIë¡œ ì˜ˆì¸¡ ê°€ëŠ¥? Predictive modeling?"
4. "**Pan-coronavirus vaccine** ê°œë°œ í˜„í™©? AI ì„¤ê³„ ì„±ê³µ ì‚¬ë¡€?"
5. "**ê·œì œ ì¸¡ë©´**: AI ì„¤ê³„ ë°±ì‹ ì˜ FDA/MFDS ìŠ¹ì¸ ê²½ë¡œ? ê²€ì¦ ìš”êµ¬ì‚¬í•­?"

---

### ğŸ”¹ ë°œí‘œ 4 (15:20-15:50)

**ì—°ì‚¬**: Kee-Jong Hong (í™ê¸°ì¢…)
**ì†Œì†**: Gachon University (ê°€ì²œëŒ€í•™êµ)
**ì œëª©**: Emerging viruses and pandemic preparedness: Vaccine R&D strategy for the pandemic responsiveness in Korea

#### ì˜ˆìƒ ë‚´ìš©

**1. í•œêµ­ì˜ Emerging Viruses**
- **SFTS** (Severe Fever with Thrombocytopenia Syndrome): ì§„ë“œê¸° ë§¤ê°œ
- **HFRS** (Hemorrhagic Fever with Renal Syndrome): í•œíƒ€ë°”ì´ëŸ¬ìŠ¤
- **AI** (Avian Influenza): H5N1, H5N6

**2. Pandemic Preparedness Framework**
```yaml
Surveillance:
  - ì¡°ê¸° ê°ì§€ ì‹œìŠ¤í…œ
  - Genomic surveillance (ë³€ì´ ì¶”ì )

R&D Platform:
  - mRNA, nanoparticle, vectored vaccines
  - Rapid prototyping (100ì¼ ëª©í‘œ)

Manufacturing:
  - Domestic capacity (SK bioscience, ë“±)
  - Fill & finish

Distribution:
  - Cold chain
  - Equity
```

**3. í•œêµ­ ë°±ì‹  R&D ì „ëµ**
- **Platform diversification**
- **Public-private partnership**
- **International collaboration** (IVI, CEPI)

**4. Regulatory Readiness**
- **Fast-track approval**
- **EUA** (Emergency Use Authorization)

---

## ğŸ§  ì„¸ì…˜ ì „ì²´ í•µì‹¬ ìš”ì•½

### S7ì˜ í•µì‹¬ ë©”ì‹œì§€

**"AIì™€ êµ¬ì¡°ìƒë¬¼í•™ì´ ë°±ì‹  ê°œë°œì„ í˜ì‹ í•˜ê³  ìˆë‹¤"**

| ë°œí‘œ | ì£¼ì œ | í˜ì‹  ìš”ì†Œ |
|------|------|----------|
| **Hwang** | Host-directed therapy | Broad-spectrum (STT3A/B) |
| **Park** | HBV receptor êµ¬ì¡° | Structure-based inhibitors |
| **Baek** | AI ë°±ì‹  ì„¤ê³„ | AlphaFold, RoseTTAFold |
| **Hong** | íŒ¬ë°ë¯¹ ëŒ€ë¹„ | ì‹ ì† í”Œë«í¼, êµ­ê°€ ì „ëµ |

### í†µí•© ê´€ì 

**ë°±ì‹  ê°œë°œì˜ íŒ¨ëŸ¬ë‹¤ì„ ì „í™˜**:
```
1. Target Identification (Baek - AI)
   â†“
2. Structure Determination (Park - Cryo-EM)
   â†“
3. Antigen Design (Baek - Structure-based)
   â†“
4. Platform Selection (Hong - mRNA, nanoparticle)
   â†“
5. Clinical Development (IVI - Trials)
```

**Host + Virus í†µí•© ì ‘ê·¼**:
- **Virus**: êµ¬ì¡° ê¸°ë°˜ í•­ì› ì„¤ê³„
- **Host**: HDTë¡œ ê°ì—¼ ì–µì œ
- **Synergy**: ì¡°í•© ìš”ë²•

---

## ğŸ“š ì‚¬ì „ ì½ê¸°

### í•„ìˆ˜
1. **Seungmin Hwang (2025)** - PNAS, "Shared host genetic landscape"
2. **Minkyung Baek (2021)** - Science, "Accurate prediction of protein structures...RoseTTAFold"
3. **AlphaFold2 (2021)** - Nature, "Highly accurate protein structure prediction"

### ì¶”ì²œ
4. **RSV vaccine (2023)** - N Engl J Med, "mRNA-1345 vaccine"
5. **COVID-19 vaccine design** - Nature, "Structure-based design of prefusion-stabilized SARS-CoV-2 spikes"

---

## ğŸ¤ Top 5 Questions

1. **[Hwang]** "STT3A/B inhibitor ê°œë°œ í˜„í™©? Clinical trials?"
2. **[Baek]** "AlphaFold3 vs. RoseTTAFold? ë°±ì‹  ì„¤ê³„ ì°¨ë³„ì ?"
3. **[Baek]** "Pan-coronavirus vaccine AI ì„¤ê³„? Success cases?"
4. **[Hong]** "í•œêµ­ mRNA ë°±ì‹  í”Œë«í¼? Domestic capability?"
5. **[All]** "AI + HDT combination: Rapidly deployable broad-spectrum platform?"

---

## ğŸ¤ ë„¤íŠ¸ì›Œí‚¹ ìš°ì„ ìˆœìœ„

1. **Minkyung Baek** (ì„œìš¸ëŒ€) â­â­â­ - êµ­ë‚´, AI ì „ë¬¸ê°€, ASPIRE Prize
2. **Seungmin Hwang** (Broad) â­â­â­ - HDT ì„ êµ¬ì
3. **Jae-Hyun Park** (ì„±ê· ê´€ëŒ€) â­â­ - êµ­ë‚´, êµ¬ì¡°ìƒë¬¼í•™
4. **Kee-Jong Hong** (ê°€ì²œëŒ€) â­â­ - êµ­ë‚´, ì •ì±…/ì „ëµ

---

**ì˜ˆìƒ í•™ìŠµ ì„±ê³¼**:
âœ… AI ë°±ì‹  ì„¤ê³„ ìµœì‹  ë™í–¥ (AlphaFold, RoseTTAFold)
âœ… Host-directed therapy ì „ëµ (STT3A/B)
âœ… Structure-based vaccine design ë°©ë²•ë¡ 
âœ… í•œêµ­ íŒ¬ë°ë¯¹ ëŒ€ì‘ ì²´ê³„

**ë°”ì´ëŸ¬ìŠ¤/ë°±ì‹  ì—°êµ¬ì í•„ìˆ˜!** ğŸ’‰
